Bibliografisk note

Funding Information:
Dr Windfeld-Mathiasen has received funding from the Rigshospitalet Research Foundation; and has received a research grant from Antidoping Denmark outside of the submitted work. Dr de Knegt has received lecture fees from Canon Medical Systems. Dr Sigvardsen has received consulting fees from Novo Nordisk and Janssen Pharmaceuticals outside of the submitted work. Dr Køber has received personal fees for presentation at symposiums outside of the submitted work. Dr Kofoed has received research grants from AP Møller og hustru Chastine McKinney Møllers Fond, The John and Birthe Meyer Foundation, the Rigshopitalet Research Council, the University of Copenhagen, the Danish Heart Foundation, and the Danish Agency for Science, Technology, and Innovation by the Danish Council for Strategic Research; has reported being the principal investigator of the investigator-initiated CATCH-2 trial and the CSub320 trial; and has reported membership on the steering committee of the CORE320 trial, which is supported in part by Canon Medical Corporation. Drs Linde and Kühl have reported that they have no relationships relevant to the contents of this paper to disclose.